Zydus Lifesciences gets USFDA’s final nod for Famotidine Tablets

06 Jun 2022 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Famotidine Tablets in the strengths of 20mg and 40mg. Famotidine is a histamine H2 receptor blocker. It works by reducing the amount of acid in the stomach. It is used to prevent and treat heartburn and other symptoms caused by excessive acid in the stomach (acid indigestion). The drug will be manufactured at group’s drug formulation facility at SEZ, Ahmedabad.

Famotidine Tablet has a market size of $67 million (as per IQVIA MAT April 2022). The group now has 315 approvals and has so far filed over 420 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

888.00 -5.45 (-0.61%)
28-Jan-2026 10:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1616.75
Dr. Reddys Lab 1226.10
Cipla 1319.25
Zydus Lifesciences 888.00
Lupin 2125.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×